Arctic Bioscience

In this MedWatch Norge interview, Christer Valderhaug provides an update on the HeROPA study and offers insights into the future direction of Arctic Bioscience, highlighting strategies across both the nutraceutical and pharmaceutical development. "Unlike many other clinical-phase companies, we already have a growing business: our phospholipid supplements are sold globally, with strong growth in Asia, especially China. We have high expectations and strong ambitions within this segment," says Christer Valderhaug, CEO of Arctic Bioscience.   Key takeaways from the interview: - Optimism remains strong despite recent challenges. - The HeROPA study will run for the full 12 months. - Potential partnerships with pharmaceutical companies for a Phase 3 trial, contingent on positive results from the 12-month study. - The nutraceutical division ensures cash flow, growing annually by approximately 30%, with a strong foothold in the U.S., Asia, and Europe.   Read the full interview below (behind paywall): #ArcticBioscience #ClinicalResearch #Psoriasis 

This year, World Psoriasis Day focuses on psoriatic disease and family. Arctic Bioscience joins in recognizing the everyday challenges of the patients living with this chronic disease, and their families. We are committed to conducting research in inflammation and psoriasis. We are very proud to present data at the Congress of the European Academy of Dermatology & Venerology in Amsterdam, September 25-28th, 2024. Psoriasis- og eksemforbundet (PEF) #worldpsoriasisday #psoriasisresearch #Inflammation #Forskingsrådet

Arctic Bioscience Q3 operational update!   Highlights from Q3 2024 include: - Nutra revenues YTD Q3 are NOK 27,8 million (NOK 23,9 million), expecting a growth of 25-30 % end of 2024 compared to 2023 - Asian markets with strong development; expecting 65-70 % growth compared to 2023 - European market also developing well; expecting 45 % growth compared to 2023 - The company has available liquidity giving runway into Q1 2025. Financing needs to finalize the phase 2b HeROPA-study and to bring the company into a positive operational cash flow is estimated at NOK 30 million As communicated mid-October, the HeROPA study did not meet its primary end-point after 6 months due to an unexpectedly high placebo rate. The study will continue as planned for 52 weeks for the final read-out due in Q1 2025 and thus including the autumn and winter season for the majority of patients participating. “After the complete data read-out beyond 52 weeks is conducted, we believe this data will provide more answers and may also give another development in total for the HeROPA-study. We still have strong confidence in our phospholipid-based technology platform for resolving inflammation, also supported by conducted and published cellular studies", says CEO Christer Valderhaug.   Read the full operational update by accessing the link in the comments section.  

Arctic Bioscience announces 6-month read-out of the HeROPA study. The high-dose active treatment arm showed an effect close to the assumed effect level after 26 weeks. However, the placebo rate was unexpectedly high, preventing the primary endpoint from being statistically significant. Arctic Bioscience will conduct a deeper analysis of the results in the coming weeks and will proceed with the study for the planned 12-month placebo-controlled treatment period. "We have strong confidence in our phospholipid-based technology platform for resolving inflammation. Thus, the study will proceed, given the promising effects observed in the treatment arm at the 6-month read-out. This is a 52-week trial, and based on prior clinical studies, we expect to see improved effects as the study progresses”, says CEO Christer Valderhaug. CEO Christer Valderhaug and Medical Director Runhild Gammelsæter, will present the findings of the study and next steps during a webcast on Wednesday, October 16, at 12:00 CET. A separate invitation will be published at Newsweb. Read the full stock exchange notice by clicking the link below.

Arctic Bioscience lager "gull av det norske arvesølvet"! For å utvikle kosttilskuddet Romega® og legemiddelkandidater på Sunnmøre, er vi avhengige av gode, langsiktige partnere. SpareBank 1 SMN er en slik partner. Se filmen om samarbeidet vårt under, og les mer om Arctic Bioscience' historie sammen med Sparebank 1 SMN i lenken i kommentarfeltet. In English: Arctic Bioscience is turning "the silver of the sea into gold"! To develop the nutraceutical supplement Romega®, alongside pharmaceutical candidates in Sunnmøre, we rely on strong, long-term partners. SpareBank 1 SMN is such a partner. Watch the video about our collaboration below, and read more about Arctic Bioscience's journey with SpareBank 1 SMN in the link in the comments section.   #Romega #arcticbioscience #Sparebank1SMN

We are happy to announce Groupe Berkem as our new sales and distribution partner for the B2B nutraceutical market in North America. Their experience with natural extracts and highly competent salesforce will bring Romega - our unique, highly bioavailable, phospholipid herring caviar oil - closer to the largest nutraceutical market in the world.   This new partnership will be launched at Supply Side West in Las Vegas on October 30th.   #romega #ArcticBioscience #HerringCaviarOil #groupeberkem

Great to present Romega at Vitafoods Asia in Bangkok this week. Delighted to welcome the Royal Norwegian Embassy in Bangkok, alongside the Thai-Norwegian Chamber of Commerce at our stand. #romega #ArcticBioscience #HerringCaviarOil

H1 2024 Highlights: Moving Toward a Significant Milestone! Arctic Bioscience today share key highlights from our H1 2024 report, marking significant progress in our journey toward a potential breakthrough in psoriasis treatment. The HeROPA clinical trial, which completed recruitment in January, is advancing as planned and de-risked by sufficient number of patients passing the 6 months milestone. The primary endpoint read-out expected in 4 to 6 weeks. This milestone brings us closer to realizing the potential of HRO350 as a transformative therapy. "The crucial milestone we've worked toward over the past few years is now within reach. We eagerly anticipate the results of this primary endpoint readout and look forward to continuing this exciting journey of development as we move toward the potential commercialization of a blockbuster drug," says Christer Valderhaug, CEO of Arctic Bioscience. Other highlights from H1 2024 include: - Recently published mode-of-action research showed positive effects on cells related to resolution of inflammation of phospholipid esters from HRO350 - Nutra revenues in H1 2024 totalling NOK 16,7 million (NOK 19,1 million). Revenue prospects for H2 2024 are positive - Booked sales and received purchase orders at end of the first half of 2024 secures total sales revenues above total sales in 2023 - Stable gross margin development in H1 2024 at 30,6 % (30,0 %) - Arctic Algae discovery of new microalgae species opens up for new and exciting future commercial opportunities and IP   Read the full report at our website and watch the webcast 11.00 CET by using this link: https://lnkd.in/dkSYrfV5

TREASURE HUNT AT SEA: Exciting report on TV2 about our founder Hogne Hallaråker's and Arctic Bioscience discovery and patent on a new microalgae found off the coast of Sunnmøre. Hogne tells TV2 that he has high hopes for the algae:   “We know that the unique membrane fat found in microalgae normalizes the immune system”, says Hogne to TV2. Intensive work is underway at the laboratory in Hovdebygda to develop future pharmaceutical and nutraceutical products.   “Our goal is to have a commercial product on the market within two to three years. In addition to our lab manager Sofie Kjerstad Berg, we have recruited researchers from Malaysia and Australia. It’s a fantastic team that will continue to work on this,” says Hogne.   The new algae discovery is just one of the many products we at Arctic Bioscience are working on.   LINK https://lnkd.in/da2UAZeH Also check Norwegian TV2 - the 9pm News from July 22nd

Exiting news! Yesterday, Arctic Bioscience presented new positive data at the 9th European Workshop on Lipid Mediators in Edinburgh, UK. Conclusions from the 3-year research project shows anti-inflammatory effects of phospholipid esters from herring roe in immune cells. "These data are important because they illuminate a mechanism of action of HRO350, which is currently being tested in a phase 2b clinical trial for mild-to-moderate psoriasis", says Runhild Gammelsaeter, Medical Director at Arctic Bioscience. The HeROPA clinical trial on HRO350 with the active substance Phospholipid Esters from Herring Roe (PeHeRo) is ongoing in mild-to-moderate psoriasis, with planned read-out fall 2024.